{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-001200","form_type":"8-K","ticker":"BNGO","cik":"0001411690","company_name":"Bionano Genomics, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.108078+00:00","generated_at":"2026-06-07T02:08:28.578599+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bionano prelim Q4 rev $10.4-10.7M (+27-30% YoY); OGM base 326 (+36%)","bullets":["Prelim Q4 2023 rev $10.4-10.7M vs $8.2M Q4 2022; FY rev $35.8-36.1M (+29-30%).","OGM installed base 326 as of year-end 2023, up 36% from 240 in 2022.","Q4 flowcell sales 7,980, up 67% from 4,781 in Q4 2022.","Cash, equivalents & securities ~$102.8M at Dec 31, 2023; $36.1M restricted.","Raised net $11.0M from ATM in Nov-Dec 2023 and $2.9M additional in Jan 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-001200","json":"https://secwatch.observer/filing/0001140361-24-001200.json","markdown":"https://secwatch.observer/filing/0001140361-24-001200.md","text":"https://secwatch.observer/filing/0001140361-24-001200.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411690/000114036124001200/0001140361-24-001200-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411690/000114036124001200/ef20018237_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:08:28.578599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"17a9e64c1e7479087e8521777923cc7c219cee3a","claim":"Bionano Genomics, Inc. reported the fourth quarter of 2023 results: revenue in the range of $10.4 million to $10.7 million.","evidence_excerpt":"Revenues for the fourth quarter 2023 are expected to be in the range of $10.4 million to $10.7 million, an estimated increase of 27% to 30% compared to $8.2 million in the fourth quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036124001200/0001140361-24-001200-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2023"},{"label":"Revenue","value":"in the range of $10.4 million to $10.7 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"7e5031452552ce86ba78e5a8505c09f691036545","claim":"Bionano Genomics, Inc. reported the fiscal year ended December 31, 2023 results: revenue in the range of $35.8 million and $36.1 million.","evidence_excerpt":"Full year 2023 revenue is expected to be in the range of $35.8 million and $36.1 million, an estimated increase of 29% to 30% compared to full year 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036124001200/0001140361-24-001200-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Revenue","value":"in the range of $35.8 million and $36.1 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}